Intervention Review

You have free access to this content

Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals

  1. Charles I Okwundu1,2,*,
  2. Olalekan A Uthman1,
  3. Christy AN Okoromah3

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 11 JUL 2012

Assessed as up-to-date: 17 OCT 2012

DOI: 10.1002/14651858.CD007189.pub3


How to Cite

Okwundu CI, Uthman OA, Okoromah CAN. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD007189. DOI: 10.1002/14651858.CD007189.pub3.

Author Information

  1. 1

    Faculty of Health Sciences, Stellenbosch University, Centre for Evidence-Based Health Care, Tygerberg, South Africa

  2. 2

    South African Medical Research Council, South African Cochrane Centre, Tygerberg, Western Cape, South Africa

  3. 3

    College of Medicine, University of Lagos, Department of Paediatrics and Child Health, Lagos, Lagos, Nigeria

*Charles I Okwundu, ciokwundu@sun.ac.za.

Publication History

  1. Publication Status: Edited (no change to conclusions), comment added to review
  2. Published Online: 11 JUL 2012

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Forest plot of comparison: 1 TDF+ FTC vs placebo, outcome: 1.1 HIV infection (by risk group).
[Figure 5]
Figure 5. Forest plot of comparison: 2 TDF vs placebo, outcome: 2.1 HIV infection.
[Figure 6]
Figure 6. Forest plot of comparison: 1 TDF+ FTC vs placebo, outcome: 1.2 HIV infection (by gender).
[Figure 7]
Figure 7. Forest plot of comparison: 2 TDF-FTC vs placebo, outcome: 2.2 Adverse events.
[Figure 8]
Figure 8. Forest plot of comparison: 1 TDF vs placebo, outcome: 1.2 Adverse events.
[Analysis 1.1]
Analysis 1.1. Comparison 1 TDF+ FTC vs placebo, Outcome 1 HIV infection (by risk group).
[Analysis 1.2]
Analysis 1.2. Comparison 1 TDF+ FTC vs placebo, Outcome 2 HIV infection (by gender).
[Analysis 1.3]
Analysis 1.3. Comparison 1 TDF+ FTC vs placebo, Outcome 3 Serious adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 TDF vs placebo, Outcome 1 HIV infection.
[Analysis 2.2]
Analysis 2.2. Comparison 2 TDF vs placebo, Outcome 2 Serious adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 TDF-FTC vs TDF alone, Outcome 1 HIV infection.
[Analysis 3.2]
Analysis 3.2. Comparison 3 TDF-FTC vs TDF alone, Outcome 2 Serious adverse events.